M9466 Alone or in Combination in Advanced Solid Tumors (DDRiver 501)

2024-513492-41-00 Protocol MS202659_0001 Human pharmacology (Phase I) - Other Ongoing, recruitment ended

Start 19 Nov 2024 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 7 sites · Protocol MS202659_0001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruitment ended
Participants planned 145
Countries 1
Sites 7

Advanced solid tumors

Key facts

Sponsor
Merck Healthcare KGaA
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
19 Nov 2024 → ongoing
Decision date (initial)
2024-09-10
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-513492-41-00
ClinicalTrials.gov
NCT06421935

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced solid tumors

VersionLevelCodeTermSystem organ class
21.1 LLT 10065252 Solid tumor 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Merck Healthcare KGaA

Sponsor organisation
Merck Healthcare KGaA
Address
Frankfurter Strasse 250
City
Darmstadt
Postcode
64293
Country
Germany

Scientific contact point

Organisation
Merck Healthcare KGaA
Contact name
Global Regulatory Affairs

Public contact point

Organisation
Merck Healthcare KGaA
Contact name
Global Regulatory Affairs

Locations

1 EU/EEA country · 7 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ongoing, recruitment ended 50 7
Rest of world
Japan, United States, Australia, Korea, Republic of
95

Investigational sites

Spain

7 sites · Ongoing, recruitment ended
Hospital Universitario 12 De Octubre
Oncology, Avenida De Cordoba Sn, 28041, Madrid
Hospital Universitario Quironsalud Madrid
Unidad de Ensayos Clínicos Fases I, Calle De Diego De Velazquez 1, 28223, Pozuelo De Alarcon
Hospital Universitario Fundacion Jimenez Diaz
Oncology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Universitari Vall D Hebron
Oncology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Institut Catala D'oncologia
Oncology, Avinguda De La Gran Via De L'hospitalet 199-203, 08908, L'hospitalet De Llobregat
Hospital Hm Nou Delfos
Oncology, Avinguda De Vallcarca 151, 08023, Barcelona
Hospital Universitario Hm Sanchinarro
Oncology, Calle Ona 10, 28050, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2024-11-19 2024-11-22 2025-11-21

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-06-13 Spain Acceptable
2024-09-10
2024-09-10
2 SUBSTANTIAL MODIFICATION SM-1 2024-11-20 Spain Acceptable
2024-12-23
2025-01-30
3 NON SUBSTANTIAL MODIFICATION NSM-1 2025-03-13 Spain Acceptable
2024-12-23
2025-03-13
4 SUBSTANTIAL MODIFICATION SM-2 2025-07-11 Spain Acceptable
2025-08-21
2025-08-28
5 SUBSTANTIAL MODIFICATION SM-3 2026-02-23 Spain Acceptable
2026-05-18
2026-05-25